Castle Biosciences (NASDAQ:CSTL) Insider Tobin Juvenal Sells 17,310 Shares

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Tobin Juvenal sold 17,310 shares of the business’s stock in a transaction on Friday, July 31st. The stock was sold at an average price of $29.31, for a total value of $507,356.10. Following the completion of the transaction, the insider owned 80,725 shares of the company’s stock, valued at $2,366,049.75. This represents a 17.66% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Stock Performance

Shares of Castle Biosciences stock traded up $0.76 during trading on Tuesday, hitting $31.15. 627,364 shares of the company’s stock traded hands, compared to its average volume of 403,923. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.04 and a quick ratio of 5.85. Castle Biosciences, Inc. has a 1 year low of $17.72 and a 1 year high of $44.28. The stock has a market capitalization of $944.78 million, a P/E ratio of -47.20 and a beta of 0.98. The business has a 50-day simple moving average of $22.97 and a 200-day simple moving average of $26.37.

Castle Biosciences (NASDAQ:CSTL) last released its quarterly earnings data on Thursday, July 30th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.41) by $0.34. Castle Biosciences had a negative return on equity of 4.15% and a negative net margin of 5.43%.The company had revenue of $99.86 million during the quarter, compared to the consensus estimate of $86.23 million. As a group, analysts forecast that Castle Biosciences, Inc. will post -1.56 EPS for the current year.

Analysts Set New Price Targets

Several research firms have recently weighed in on CSTL. KeyCorp set a $35.00 price objective on shares of Castle Biosciences in a report on Friday, May 29th. BTIG Research lifted their target price on shares of Castle Biosciences from $40.00 to $44.00 and gave the stock a “buy” rating in a research report on Monday. Canaccord Genuity Group decreased their target price on shares of Castle Biosciences from $50.00 to $40.00 and set a “buy” rating for the company in a research note on Monday, April 20th. Wall Street Zen raised Castle Biosciences from a “sell” rating to a “hold” rating in a report on Saturday. Finally, Weiss Ratings upgraded Castle Biosciences from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Friday. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $42.00.

Hedge Funds Weigh In On Castle Biosciences

Institutional investors and hedge funds have recently made changes to their positions in the business. Vanguard Group Inc. increased its holdings in Castle Biosciences by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 2,199,829 shares of the company’s stock valued at $85,573,000 after buying an additional 27,511 shares during the last quarter. RTW Investments LP purchased a new position in shares of Castle Biosciences during the 4th quarter worth $82,283,000. Principal Financial Group Inc. boosted its stake in shares of Castle Biosciences by 0.7% during the 4th quarter. Principal Financial Group Inc. now owns 1,807,644 shares of the company’s stock worth $70,317,000 after acquiring an additional 13,289 shares during the last quarter. Dimensional Fund Advisors LP grew its position in shares of Castle Biosciences by 7.0% during the 3rd quarter. Dimensional Fund Advisors LP now owns 1,474,089 shares of the company’s stock valued at $33,564,000 after acquiring an additional 96,084 shares during the period. Finally, Summit Partners Public Asset Management LLC grew its position in shares of Castle Biosciences by 164.7% during the 4th quarter. Summit Partners Public Asset Management LLC now owns 1,058,725 shares of the company’s stock valued at $41,184,000 after acquiring an additional 658,725 shares during the period. Hedge funds and other institutional investors own 92.60% of the company’s stock.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.